Sam Lanyon
Chairman en LUMOS DIAGNOSTICS HOLDINGS LIMITED .
Perfil
Sam Lanyon is the founder.
He founded Planet Innovation Pty Ltd.
in 2009 and holds the title of Executive Director.
Currently, Mr. Lanyon is the Executive Chairman at Lumos Diagnostics, Lumos Diagnostics Holdings Ltd., and Director at Visus Therapeutics, Inc. In the past, he worked as a Director at Waterwerx Pty Ltd.
and Zen Ecosystems.
Mr. Lanyon's education includes an undergraduate degree from the University of Melbourne.
Cargos activos de Sam Lanyon
Empresas | Cargo | Inicio |
---|---|---|
LUMOS DIAGNOSTICS HOLDINGS LIMITED | Chairman | 01/01/2019 |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | Director/Board Member | - |
Lumos Diagnostics
Lumos Diagnostics Medical SpecialtiesHealth Technology Lumos Diagnostics develops and provides diagnostic solutions. It offers assay development, reader development, and point-of-care diagnostic solutions. The company is headquartered in Carlsbad, CA. | Chairman | - |
Planet Innovation Pty Ltd.
Planet Innovation Pty Ltd. Medical SpecialtiesHealth Technology Planet Innovation Pty Ltd. is a healthtech innovation and Australian commercialization company that specializes in product development and manufacturing. The private company is based in Box Hill, AU. and has subsidiaries in the United States. It was founded in 2009 by Eduardo Vom, Sam Lanyon, Stuart Elliott, and Troy O'Callaghan, with Stuart Elliott serving as the CEO since its inception. | Founder | 01/01/2009 |
Antiguos cargos conocidos de Sam Lanyon.
Empresas | Cargo | Fin |
---|---|---|
Zen Ecosystems | Director/Board Member | - |
Waterwerx Pty Ltd. | Director/Board Member | - |
Formación de Sam Lanyon.
University of Melbourne | Undergraduate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
LUMOS DIAGNOSTICS HOLDINGS LIMITED | Health Technology |
Empresas privadas | 5 |
---|---|
Waterwerx Pty Ltd. | |
Planet Innovation Pty Ltd.
Planet Innovation Pty Ltd. Medical SpecialtiesHealth Technology Planet Innovation Pty Ltd. is a healthtech innovation and Australian commercialization company that specializes in product development and manufacturing. The private company is based in Box Hill, AU. and has subsidiaries in the United States. It was founded in 2009 by Eduardo Vom, Sam Lanyon, Stuart Elliott, and Troy O'Callaghan, with Stuart Elliott serving as the CEO since its inception. | Health Technology |
Lumos Diagnostics
Lumos Diagnostics Medical SpecialtiesHealth Technology Lumos Diagnostics develops and provides diagnostic solutions. It offers assay development, reader development, and point-of-care diagnostic solutions. The company is headquartered in Carlsbad, CA. | Health Technology |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | Health Technology |
Zen Ecosystems |
- Bolsa de valores
- Insiders
- Sam Lanyon